On Wednesday, Shares of Halliburton Company (NYSE:HAL), lost -0.22% to $44.97.
Halliburton Company, declared that it has reached a contract with BP Exploration & Production Inc. to resolve remaining issues, which comprises indemnities between the parties and dismissal of all claims against each other, regarding the April 20, 2010, Deepwater Horizon well incident in the Gulf of Mexico.
Halliburton formerly declared that it reached a contract to settle punitive damages claims against Halliburton by a class of plaintiffs who allege damages to property or associated with the commercial fishing industry arising from the Deepwater Horizon incident, and all claims against Halliburton that BP assigned to the settlement class in BP’s April 2012 settlement with the Plaintiffs’ Steering Committee.
Halliburton Company provides a range of services and products to the upstream oil and natural gas industry worldwide. The company operates through two segments, Completion and Production, and Drilling and Evaluation.
Shares of Boston Scientific Corporation (NYSE:BSX), declined -0.77% to $17.98, during its last trading session.
Boston Scientific Corporation, stated positive, long-term data from the EVOLVE Trial of the SYNERGY™ Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium Coronary Stent System, with no new major adverse cardiac events stated between years three and four. The study results were presented for the first time recently at EuroPCR 2015 by Professor Ian Meredith, director of MonashHeart, at Monash Medical Centre in Melbourne, Australia.
Findings from year four of the EVOLVE Trial comprise the following key performance measures:
- the target lesion revascularization (TLR) rate was 1.1 percent contrast to 6.1 percent for the PROMUS Element™ Plus Stent System (p=0.07); and
- no definite or probable stent thrombosis (ST) was observed.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Administration, and MedSurg.
At the end of Wednesday’s trade, Shares of Celladon Corporation (NASDAQ:CLDN), gained 13.73% to $2.32.
Celladon Corporation, declared financial results for the quarter ended March 31, 2015 and recent corporate updates.
First Quarter 2015 Financial Results
- Cash Position: Cash, cash equivalents and investments as of March 31, 2015 were $70.6 million.
- Research and Development Expenses: Research and development expenses were $11.5 million and $5.2 million, respectively, for the first quarter of 2015 and 2014.
- General and Administrative Expenses: General and administrative expenses were $4.8 million and $1.7 million, respectively, for the first quarter of 2015 and 2014.
- Other Expense, Net: Other expense, net was $449 thousand and $238 thousand for the first quarter of 2015 and 2014, respectively.
- Merged Net Loss: Merged net loss was $16.7 million and $7.2 million for the first quarter of 2015 and 2014, respectively. The merged net loss comprised of stock-based compensation of $2.1 million and $0.5 million for the first quarter of 2015 and 2014, respectively.
Celladon Corporation, a clinical-stage biotechnology company, focuses on developing cardiovascular gene therapy and calcium dysregulation. The company’s lead product candidate comprises MYDICAR that uses genetic enzyme replacement therapy to correct the Sarco/endoplasmic reticulum Ca 2+ -ATPase 2a enzyme deficiency in heart failure patients that result in inadequate pumping of the heart.
Finally, Banro Corporation (NYSEMKT:BAA), ended its last trade with 3.09% gain, and closed at $0.37.
Banro Corporation, declared that Mick Oliver has been designated to the Company’s board of directors as an additional independent director.
Mr. Oliver has 38 years’ experience in the mining sector. From 1996 to 2014, he held senior positions with CIBC World Markets Inc., becoming in 2011 Managing Director (Head of Mining Team) in the global mining investment banking group. Preceding to this, he worked for 10 years with HSBC covering natural resources, where, from 1990 to 1996, he was a Partner, Corporate Finance. Mr. Oliver is presently Managing Director of Natural Resources Global Capital Partners, an independent advisory business offering financial and technical advice to the global natural resource sector. Mr. Oliver began his career as a mining engineer, with eight years of managerial experience in precious and base metals in Zambia and South Africa. He graduated from Nottingham University in 1976 with a joint mining/geology degree and from the University of the Witswatersrand, South Africa in 1985 with an MBA. He is a Fellow of the Institute of Mining & Metallurgy and a Chartered Engineer, and holds a Mine Manager’s Certificate from South Africa.
Banro Corporation, together with its auxiliaries, engages in the exploration, development, and production of mineral properties. It primarily explores for gold. The company holds a 100% interest in 4 gold properties, counting Twangiza, Namoya, Lugushwa, and Kamituga comprising 13 exploitation permits that cover an area of about 2,612 square kilometers in the South Kivu and Maniema provinces of the Democratic Republic of the Congo. It also owns 14 exploration permits covering an area of about 2,638 square kilometers located between the Twangiza and Namoya properties.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
